SlideShare a Scribd company logo
Statistics in Meta-analysis and
the forest plot
Dr. Imran Rizvi
Assistant professor, Neurology
KGMU
Outline
• Statistics in meta-analysis
• Visual display of the results: Forest plot
• How to do the analysis: RevMan
Introduction
Meta-analysis
• Type of secondary research.
• The statistical combination of results from two or
more separate studies.
Effect/ Treatment Effect
Meta-analysis answers the following
questions
• What is the direction of effect?
• What is the size of effect?
• Is the effect consistent across studies?
Statistics in meta-analysis
Meta-analysis is a 2 stage process.
1. Calculate an effect estimate (summary statistics) for
each study (RR, OR, HR etc for each study)
2. Calculate the overall treatment effect (usually as a
weighted average of these summary statistics).
Calculating effect measure of individual
studies
• Calculation of effect measure depends upon the type of
outcome data.
• Outcome data can be of following 4 types.
Dichotomous (Binary data)
Continuous data
Ordinal data
Time to event (survival rate)
Types of outcome Definition and example
Dichotomous (Binary) When the outcome for every participant
falls in one of two possibilities.
Example: Dead/Living
Clinical Improvement/No clinical
improvement.
Continuous Data that can take any value in a specified
range.
Example: BP reduction following T/t
Blood sugar reduction following T/t
Ordinal Ordinal outcome data arise when each
participant is classified in a category and
when the categories have a natural order.
Mild/moderate/severe
Pain scales/ disability scales
Time to event Time elapsed before an event is
experienced.
Time to death after cancer/MI
Effect measures used according to the type of outcome
Type of Outcome Effect measure (Summary)
commonly used
Dichotomous (Binary) Risk Ratio= Relative Risk= RR
Odds ratio
Risk difference (ARR)
NNT
Continuous The mean difference and the
standardized mean difference.
Ordinal Proportional Odds ratio
Longer ordinal scales: continuous data
Shorter ordinal scales: can be clubbed
into 2 categories to be analysed as
dichotomous data
Time to event Hazard ratio
Risk Ratio/ Relative Risk
• Most commonly used measure when the outcome is
dichotomous.
• Ratio of risk of event in the experimental group to Risk of
event in the control group.
• RR= Risk in exposed/ Risk in non exposed
RR= A/A+B
C/C+D
Treatment Event No event Total
Intervention arm A B A+B
Control arm C D C+D
Example
• 545 TBM patients were randomly assigned to receive
dexamethasone (N=274) Or placebo (N=271).
• The primary outcome measure was death.
• 87 deaths occurred in the dexamethasone arm, 112
deaths occurred in the placebo arm.
• What is the RR ?
RR calculation
Treatm
ent
Death Alive Total
Dexa 87 187 274
Placebo 112 159 271
545
• Risk of event in
exposed=
87/274=31.75%
• Risk of event in
control=112/271=41.33
%
• RR=31.75/41.33=0.77
Interpretation
• RR=1: Risk of event in the exposed is equal to the risk of
event in the non exposed (No association).
• RR<1: Risk of event in exposed is less than risk of event
in the non exposed.
• RR>1: Risk of event in exposed is more than risk of event
in the non exposed.
Odds ratio
• Ratio of the odds of an event in the Treatment group to
the odds of an event in the control group.
• The odds of an event is the number of events divided by
the number of non-events.
• Odds ratios are most commonly used in case-control
studies.
OR calculation
Treatm
ent
Event No
event
Total
Interve
ntion
arm
A B A+B
Control
arm
C D C+D
• Odds of event in
intervention arm= A/B
• Odds of event in
control arm= C/D
• OR= odds of event in
intervention/odd of
event in control
• A/B÷C/D=AD/BC
Interpretation
• OR=1 Exposure does not affect odds of outcome.
• OR>1 Exposure associated with higher odds of outcome.
• OR<1 Exposure associated with lower odds of outcome.
Absolute Risk Reduction
• ARR is also called as Risk difference
• The difference between the risk of an event in the control
group and the risk of an event in the treated group.
ARR
Treatm
ent
Event No
event
Total
Interven
tion arm
A B A+B
Control
arm
C D C+D
• Risk of event in
controls: C/C+D
• Risk of event in
intervention: A/A+B
• ARR= C/C+D – A/A+B
Treatm
ent
Death Alive Total
Dexa 87 187 274
Placebo 112 159 271
545
• Risk of death in
controls=112/271=
41.33%
• Risk of death in
intervention=87/274=
31.75
• ARR=41.33-
31.75=9.58%
If 100 TBM cases are given dexa
about 10 will be prevented from
dying
Number needed to treat
• The NNT is the average number of patients who need to
be treated to prevent one additional bad outcome.
• NNT is the reciprocal of the absolute risk reduction (i.e.,
1/absolute risk reduction).
• The higher the NNT, the less effective is the treatment
NNT
Treatm
ent
Event No
event
Total
Interven
tion arm
A B A+B
Control
arm
C D C+D
• Risk of event in
control= C/C+D
• Risk of event in
intervention=A/A+B
• ARR=C/C+D-A/A+B
• NNT=1/ARR
NNT
Treatm
ent
Death Alive Total
Dexa 87 187 274
Placebo 112 159 271
545
• Risk of death in
controls=112/271= 41.33%
• Risk of death in
intervention=87/274=
31.75
• ARR=41.33-31.75=9.58%
• NNT=100/9.58=10.45
About 10 TBM cases needs
to be given dexa to
prevent 1 death.
Effect estimate Definition Formula Advantage
Odds ratio Ratio of odds of event
in intervention group
to odds of event in the
control group.
A/B÷C/D=AD/BC Most useful measure
for case-control study.
Risk ratio Ratio of risk of event
in intervention group
to risk of event in the
control group.
A/A+B÷C/C+D Useful in clinical
trials.
Absolute risk reduction Difference between
risk of event in control
and risk of event in
intervention group.
C/C+D-A/A+B Useful in clinical
trials.
Number needed to treat Average number of
patients that needs to
be treated to prevent
one additional poor
outcome
1/ARR Useful for clinical
trials and to convey
information to the
patient
Confidence interval
• The results of any experiment are an estimate of the truth.
• The true effect of treatment may actually be greater or
less than what we observed.
• CI Is the range of values that is likely to include the true
population value .
• CIs give us an idea of how confident we are about a
studies estimate of treatment effect.
• The narrower the range, the more precise the study’s
estimates.
• 95% CI represents the range within which we can be 95
%certain that the true answer lies.
Helps to decide significance?
Step 2: Calculation of overall t/t effect
• Overall effect is calculated by a weighted averaged of
individual studies.
• Weight of individual study= inverse of variance
Two models are commonly used to combine the effects of
individual studies
1. Fixed Effect model
2. Random Effects model
Fixed Effect model
• We assume that there is one true effect size that underlies
all the studies in the analysis.
• All the studies are evaluating the same true effect.
• Any difference observed in the effect size is due to
random error.
• Fixed effect= common effect.
• There is only one source of variance i.e sampling error.
Random effects model
• We assume that Effect size may differ from study to
study.
• For example effect size may vary according to the age of
participants, dose of drug, timing of outcome assessment.
• Random effects model allows for heterogeneity.
• Consider there are 2 sources of variance
1. Within study variance (sampling error)
2. Between study variance (Age, dose, outcome
assesment)
• To calculate the overall mean the weighted average of
individual studies is calculated.
• Weighted average = Sum of(estimate X Weight)/sum of W
• Weight = 1/Variance
Weight of studies in the 2 models
Assumption Heterogeneity Confidence
interval
Fixed effect model •One true effect
underlies all
studies.
•Differences are
due to chance.
Ignored Narrow
Random effects
mode
•Effect size varies
amongst studies.
•Difference are not
due to chance
Taken into account Wider
Which model to use ?
• If significant clinical or statistical heterogeneity is present
use the random effects model. Otherwise use fixed effect
model.
• Clinical heterogeneity: Age, population, dose of
intervention, method of outcome assessment.
• Statistical heterogeneity.
DISPLAYING THE RESULTS: FOREST PLOT
Forest plot
• The typical graph used for displaying results of a meta-
analysis: forest plot
• Blobbogram
• At one glance we can see the effect of individual studies
as well as the overall effect.
• The horizontal axis usually represents the scale of
statistics. (OR, RR, ARR, SMD etc).
• The vertical line is known as the “line of null effect.”
• This line is placed at the value where there is no
association between an exposure and outcome.
• For OR, RR the vertical line passes through 1.
• For ARR, MD the vertical line passes through 0.
Study lines
• Effect estimates of individual studies are represented by
boxes.
• Size of the box represents the weight of the study.
• The horizontal line represents the 95% confidence
intervals of the study.
• Any study line which crosses the line of null effect does
not illustrate a significant result.
The diamond
• The diamond represent the overall effect estimate.
• A vertical line through the vertical points of the diamond,
represents the overall effect.
• The horizontal points of the diamond represent the 95%
confidence interval of this combined point estimate.
• If the horizontal tips of the diamond cross the vertical line,
the combined result is not significant.
DEMO: HOW TO DO
ANALYSIS IN REVMAN
Hypothetical Meta-analysis
• Intensified ATT regimen Vs Standard ATT regimen for
management of TBM.
• P= TBM patients >18 years
• I= intensified ATT (Levofloxacin plus HRZS)
• C= standard ATT (HRZS)
• O= death at 6 months
• Search Literature
• Narrow down the articles
• Data extraction
Forest plot
THANK YOU

More Related Content

What's hot

Hypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast CancerHypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast Cancer
Dr.Ram Madhavan
 
Radiotherapy sarcomas
Radiotherapy sarcomas Radiotherapy sarcomas
Radiotherapy sarcomas
Ashutosh Mukherji
 
Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]
Upasna Saxena
 
Cancer Genetic counselling
Cancer Genetic counsellingCancer Genetic counselling
Cancer Genetic counselling
Aaditya Prakash
 
SBRT IN LIVER TUMOURS- DR UPASNA.pptx
SBRT IN LIVER TUMOURS- DR UPASNA.pptxSBRT IN LIVER TUMOURS- DR UPASNA.pptx
SBRT IN LIVER TUMOURS- DR UPASNA.pptx
Upasna Saxena
 
Hazard ratios
Hazard ratiosHazard ratios
Hazard ratios
Terry Shaneyfelt
 
cervical cancer conformal radiotherapy planning (3D CRT)
cervical cancer conformal radiotherapy planning (3D CRT)cervical cancer conformal radiotherapy planning (3D CRT)
cervical cancer conformal radiotherapy planning (3D CRT)
Gebrekirstos Hagos Gebrekirstos, MD
 
Radiotherapy in CA Penis
Radiotherapy in CA PenisRadiotherapy in CA Penis
Radiotherapy in CA Penis
DrAyush Garg
 
ONCOLOGY CARTOONS
ONCOLOGY CARTOONSONCOLOGY CARTOONS
ONCOLOGY CARTOONS
Kanhu Charan
 
Osteosarcoma ppt
Osteosarcoma pptOsteosarcoma ppt
Osteosarcoma ppt
Sameer Rastogi
 
Kaplan Meier Survival Curve Analysis
Kaplan Meier Survival Curve Analysis Kaplan Meier Survival Curve Analysis
Kaplan Meier Survival Curve Analysis
Nermin Osman
 
image guided brachytherapy carcinoma cervix
image guided brachytherapy carcinoma cerviximage guided brachytherapy carcinoma cervix
image guided brachytherapy carcinoma cervix
Isha Jaiswal
 
Chapter 24.3 metronomic chemotherapy
Chapter 24.3 metronomic chemotherapyChapter 24.3 metronomic chemotherapy
Chapter 24.3 metronomic chemotherapy
Nilesh Kucha
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUM
Kanhu Charan
 
MACHNC.pptx
MACHNC.pptxMACHNC.pptx
MACHNC.pptx
adityasingla007
 
Radioimmunotherapy
RadioimmunotherapyRadioimmunotherapy
Radioimmunotherapy
Aastha Shah
 
Oncotype Dx Mammaprint
Oncotype Dx MammaprintOncotype Dx Mammaprint
Oncotype Dx Mammaprintfondas vakalis
 
Cluster randomization trial presentation
Cluster randomization trial presentationCluster randomization trial presentation
Cluster randomization trial presentationRanadip Chowdhury
 
Neoadjuvant therapy for esophageal cancer
Neoadjuvant therapy for esophageal cancerNeoadjuvant therapy for esophageal cancer
Neoadjuvant therapy for esophageal cancer
hr77
 

What's hot (20)

Hypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast CancerHypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast Cancer
 
Radiotherapy sarcomas
Radiotherapy sarcomas Radiotherapy sarcomas
Radiotherapy sarcomas
 
Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]
 
Cancer Genetic counselling
Cancer Genetic counsellingCancer Genetic counselling
Cancer Genetic counselling
 
SBRT IN LIVER TUMOURS- DR UPASNA.pptx
SBRT IN LIVER TUMOURS- DR UPASNA.pptxSBRT IN LIVER TUMOURS- DR UPASNA.pptx
SBRT IN LIVER TUMOURS- DR UPASNA.pptx
 
Hazard ratios
Hazard ratiosHazard ratios
Hazard ratios
 
cervical cancer conformal radiotherapy planning (3D CRT)
cervical cancer conformal radiotherapy planning (3D CRT)cervical cancer conformal radiotherapy planning (3D CRT)
cervical cancer conformal radiotherapy planning (3D CRT)
 
Radiotherapy in CA Penis
Radiotherapy in CA PenisRadiotherapy in CA Penis
Radiotherapy in CA Penis
 
ONCOLOGY CARTOONS
ONCOLOGY CARTOONSONCOLOGY CARTOONS
ONCOLOGY CARTOONS
 
Osteosarcoma ppt
Osteosarcoma pptOsteosarcoma ppt
Osteosarcoma ppt
 
Kaplan Meier Survival Curve Analysis
Kaplan Meier Survival Curve Analysis Kaplan Meier Survival Curve Analysis
Kaplan Meier Survival Curve Analysis
 
image guided brachytherapy carcinoma cervix
image guided brachytherapy carcinoma cerviximage guided brachytherapy carcinoma cervix
image guided brachytherapy carcinoma cervix
 
Chapter 24.3 metronomic chemotherapy
Chapter 24.3 metronomic chemotherapyChapter 24.3 metronomic chemotherapy
Chapter 24.3 metronomic chemotherapy
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUM
 
MACHNC.pptx
MACHNC.pptxMACHNC.pptx
MACHNC.pptx
 
Radioimmunotherapy
RadioimmunotherapyRadioimmunotherapy
Radioimmunotherapy
 
Oncotype Dx Mammaprint
Oncotype Dx MammaprintOncotype Dx Mammaprint
Oncotype Dx Mammaprint
 
Radiation therapy of oral cancers
Radiation therapy of oral cancersRadiation therapy of oral cancers
Radiation therapy of oral cancers
 
Cluster randomization trial presentation
Cluster randomization trial presentationCluster randomization trial presentation
Cluster randomization trial presentation
 
Neoadjuvant therapy for esophageal cancer
Neoadjuvant therapy for esophageal cancerNeoadjuvant therapy for esophageal cancer
Neoadjuvant therapy for esophageal cancer
 

Similar to Imran rizvi statistics in meta analysis

Epidemological methods
Epidemological methodsEpidemological methods
Epidemological methods
Kundan Singh
 
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015
Isla Kuhn
 
Risk Comparison
Risk ComparisonRisk Comparison
Risk Comparison
Weam Banjar
 
statistics for MEDICAL RESEARH.... .pptx
statistics for MEDICAL RESEARH.... .pptxstatistics for MEDICAL RESEARH.... .pptx
statistics for MEDICAL RESEARH.... .pptx
dhivyaramesh95
 
How to do the maths
How to do the mathsHow to do the maths
How to do the maths
Ahmed Elfaitury
 
Research methodology3
Research methodology3Research methodology3
Research methodology3Tosif Ahmad
 
Bio-Statistics in Bio-Medical research
Bio-Statistics in Bio-Medical researchBio-Statistics in Bio-Medical research
Bio-Statistics in Bio-Medical research
Shinjan Patra
 
Statistics.pdf.pdf for Research Physiotherapy and Occupational Therapy
Statistics.pdf.pdf for Research Physiotherapy and Occupational TherapyStatistics.pdf.pdf for Research Physiotherapy and Occupational Therapy
Statistics.pdf.pdf for Research Physiotherapy and Occupational Therapy
SakhileKhoza2
 
Sample determinants and size
Sample determinants and sizeSample determinants and size
Sample determinants and size
Tarek Tawfik Amin
 
study design Case Control Study , sample size estimation.pptx
study design Case Control Study , sample size estimation.pptxstudy design Case Control Study , sample size estimation.pptx
study design Case Control Study , sample size estimation.pptx
The university of Punjab
 
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Dr. Aryan (Anish Dhakal)
 
DSE-2, ANALYTICAL METHODS.pptx
DSE-2, ANALYTICAL METHODS.pptxDSE-2, ANALYTICAL METHODS.pptx
DSE-2, ANALYTICAL METHODS.pptx
Mathabhanga College
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011
NES
 
scope and need of biostatics
scope and need of  biostaticsscope and need of  biostatics
scope and need of biostatics
dr_sharmajyoti01
 
1. complete stats notes
1. complete stats notes1. complete stats notes
1. complete stats notes
Bob Smullen
 
Biostatistics.pptx
Biostatistics.pptxBiostatistics.pptx
Biostatistics.pptx
SagarAGavankar
 
Introduction to critical appraisal
Introduction to critical appraisal   Introduction to critical appraisal
Introduction to critical appraisal
LYPFTlibrary
 
Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)
Vikash Keshri
 
Epidemiology Lectures for UG
Epidemiology Lectures for UGEpidemiology Lectures for UG
Epidemiology Lectures for UG
amitakashyap1
 
Sample size determination
Sample size determinationSample size determination
Sample size determination
Augustine Gatimu
 

Similar to Imran rizvi statistics in meta analysis (20)

Epidemological methods
Epidemological methodsEpidemological methods
Epidemological methods
 
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015
 
Risk Comparison
Risk ComparisonRisk Comparison
Risk Comparison
 
statistics for MEDICAL RESEARH.... .pptx
statistics for MEDICAL RESEARH.... .pptxstatistics for MEDICAL RESEARH.... .pptx
statistics for MEDICAL RESEARH.... .pptx
 
How to do the maths
How to do the mathsHow to do the maths
How to do the maths
 
Research methodology3
Research methodology3Research methodology3
Research methodology3
 
Bio-Statistics in Bio-Medical research
Bio-Statistics in Bio-Medical researchBio-Statistics in Bio-Medical research
Bio-Statistics in Bio-Medical research
 
Statistics.pdf.pdf for Research Physiotherapy and Occupational Therapy
Statistics.pdf.pdf for Research Physiotherapy and Occupational TherapyStatistics.pdf.pdf for Research Physiotherapy and Occupational Therapy
Statistics.pdf.pdf for Research Physiotherapy and Occupational Therapy
 
Sample determinants and size
Sample determinants and sizeSample determinants and size
Sample determinants and size
 
study design Case Control Study , sample size estimation.pptx
study design Case Control Study , sample size estimation.pptxstudy design Case Control Study , sample size estimation.pptx
study design Case Control Study , sample size estimation.pptx
 
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
Mathematics in Epidemiology and Biostatistics (Medical Booklet Series by Dr. ...
 
DSE-2, ANALYTICAL METHODS.pptx
DSE-2, ANALYTICAL METHODS.pptxDSE-2, ANALYTICAL METHODS.pptx
DSE-2, ANALYTICAL METHODS.pptx
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011
 
scope and need of biostatics
scope and need of  biostaticsscope and need of  biostatics
scope and need of biostatics
 
1. complete stats notes
1. complete stats notes1. complete stats notes
1. complete stats notes
 
Biostatistics.pptx
Biostatistics.pptxBiostatistics.pptx
Biostatistics.pptx
 
Introduction to critical appraisal
Introduction to critical appraisal   Introduction to critical appraisal
Introduction to critical appraisal
 
Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)
 
Epidemiology Lectures for UG
Epidemiology Lectures for UGEpidemiology Lectures for UG
Epidemiology Lectures for UG
 
Sample size determination
Sample size determinationSample size determination
Sample size determination
 

Recently uploaded

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 

Recently uploaded (20)

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 

Imran rizvi statistics in meta analysis

  • 1. Statistics in Meta-analysis and the forest plot Dr. Imran Rizvi Assistant professor, Neurology KGMU
  • 2. Outline • Statistics in meta-analysis • Visual display of the results: Forest plot • How to do the analysis: RevMan
  • 4. Meta-analysis • Type of secondary research. • The statistical combination of results from two or more separate studies.
  • 6. Meta-analysis answers the following questions • What is the direction of effect? • What is the size of effect? • Is the effect consistent across studies?
  • 7. Statistics in meta-analysis Meta-analysis is a 2 stage process. 1. Calculate an effect estimate (summary statistics) for each study (RR, OR, HR etc for each study) 2. Calculate the overall treatment effect (usually as a weighted average of these summary statistics).
  • 8. Calculating effect measure of individual studies • Calculation of effect measure depends upon the type of outcome data. • Outcome data can be of following 4 types. Dichotomous (Binary data) Continuous data Ordinal data Time to event (survival rate)
  • 9. Types of outcome Definition and example Dichotomous (Binary) When the outcome for every participant falls in one of two possibilities. Example: Dead/Living Clinical Improvement/No clinical improvement. Continuous Data that can take any value in a specified range. Example: BP reduction following T/t Blood sugar reduction following T/t Ordinal Ordinal outcome data arise when each participant is classified in a category and when the categories have a natural order. Mild/moderate/severe Pain scales/ disability scales Time to event Time elapsed before an event is experienced. Time to death after cancer/MI
  • 10. Effect measures used according to the type of outcome Type of Outcome Effect measure (Summary) commonly used Dichotomous (Binary) Risk Ratio= Relative Risk= RR Odds ratio Risk difference (ARR) NNT Continuous The mean difference and the standardized mean difference. Ordinal Proportional Odds ratio Longer ordinal scales: continuous data Shorter ordinal scales: can be clubbed into 2 categories to be analysed as dichotomous data Time to event Hazard ratio
  • 11. Risk Ratio/ Relative Risk • Most commonly used measure when the outcome is dichotomous. • Ratio of risk of event in the experimental group to Risk of event in the control group. • RR= Risk in exposed/ Risk in non exposed
  • 12.
  • 13. RR= A/A+B C/C+D Treatment Event No event Total Intervention arm A B A+B Control arm C D C+D
  • 14. Example • 545 TBM patients were randomly assigned to receive dexamethasone (N=274) Or placebo (N=271). • The primary outcome measure was death. • 87 deaths occurred in the dexamethasone arm, 112 deaths occurred in the placebo arm. • What is the RR ?
  • 15. RR calculation Treatm ent Death Alive Total Dexa 87 187 274 Placebo 112 159 271 545 • Risk of event in exposed= 87/274=31.75% • Risk of event in control=112/271=41.33 % • RR=31.75/41.33=0.77
  • 16. Interpretation • RR=1: Risk of event in the exposed is equal to the risk of event in the non exposed (No association). • RR<1: Risk of event in exposed is less than risk of event in the non exposed. • RR>1: Risk of event in exposed is more than risk of event in the non exposed.
  • 17. Odds ratio • Ratio of the odds of an event in the Treatment group to the odds of an event in the control group. • The odds of an event is the number of events divided by the number of non-events. • Odds ratios are most commonly used in case-control studies.
  • 18. OR calculation Treatm ent Event No event Total Interve ntion arm A B A+B Control arm C D C+D • Odds of event in intervention arm= A/B • Odds of event in control arm= C/D • OR= odds of event in intervention/odd of event in control • A/B÷C/D=AD/BC
  • 19. Interpretation • OR=1 Exposure does not affect odds of outcome. • OR>1 Exposure associated with higher odds of outcome. • OR<1 Exposure associated with lower odds of outcome.
  • 20. Absolute Risk Reduction • ARR is also called as Risk difference • The difference between the risk of an event in the control group and the risk of an event in the treated group.
  • 21. ARR Treatm ent Event No event Total Interven tion arm A B A+B Control arm C D C+D • Risk of event in controls: C/C+D • Risk of event in intervention: A/A+B • ARR= C/C+D – A/A+B
  • 22. Treatm ent Death Alive Total Dexa 87 187 274 Placebo 112 159 271 545 • Risk of death in controls=112/271= 41.33% • Risk of death in intervention=87/274= 31.75 • ARR=41.33- 31.75=9.58% If 100 TBM cases are given dexa about 10 will be prevented from dying
  • 23. Number needed to treat • The NNT is the average number of patients who need to be treated to prevent one additional bad outcome. • NNT is the reciprocal of the absolute risk reduction (i.e., 1/absolute risk reduction). • The higher the NNT, the less effective is the treatment
  • 24. NNT Treatm ent Event No event Total Interven tion arm A B A+B Control arm C D C+D • Risk of event in control= C/C+D • Risk of event in intervention=A/A+B • ARR=C/C+D-A/A+B • NNT=1/ARR
  • 25. NNT Treatm ent Death Alive Total Dexa 87 187 274 Placebo 112 159 271 545 • Risk of death in controls=112/271= 41.33% • Risk of death in intervention=87/274= 31.75 • ARR=41.33-31.75=9.58% • NNT=100/9.58=10.45 About 10 TBM cases needs to be given dexa to prevent 1 death.
  • 26. Effect estimate Definition Formula Advantage Odds ratio Ratio of odds of event in intervention group to odds of event in the control group. A/B÷C/D=AD/BC Most useful measure for case-control study. Risk ratio Ratio of risk of event in intervention group to risk of event in the control group. A/A+B÷C/C+D Useful in clinical trials. Absolute risk reduction Difference between risk of event in control and risk of event in intervention group. C/C+D-A/A+B Useful in clinical trials. Number needed to treat Average number of patients that needs to be treated to prevent one additional poor outcome 1/ARR Useful for clinical trials and to convey information to the patient
  • 27. Confidence interval • The results of any experiment are an estimate of the truth. • The true effect of treatment may actually be greater or less than what we observed. • CI Is the range of values that is likely to include the true population value . • CIs give us an idea of how confident we are about a studies estimate of treatment effect. • The narrower the range, the more precise the study’s estimates. • 95% CI represents the range within which we can be 95 %certain that the true answer lies.
  • 28. Helps to decide significance?
  • 29.
  • 30. Step 2: Calculation of overall t/t effect • Overall effect is calculated by a weighted averaged of individual studies. • Weight of individual study= inverse of variance Two models are commonly used to combine the effects of individual studies 1. Fixed Effect model 2. Random Effects model
  • 31. Fixed Effect model • We assume that there is one true effect size that underlies all the studies in the analysis. • All the studies are evaluating the same true effect. • Any difference observed in the effect size is due to random error. • Fixed effect= common effect. • There is only one source of variance i.e sampling error.
  • 32.
  • 33. Random effects model • We assume that Effect size may differ from study to study. • For example effect size may vary according to the age of participants, dose of drug, timing of outcome assessment. • Random effects model allows for heterogeneity. • Consider there are 2 sources of variance 1. Within study variance (sampling error) 2. Between study variance (Age, dose, outcome assesment)
  • 34.
  • 35. • To calculate the overall mean the weighted average of individual studies is calculated. • Weighted average = Sum of(estimate X Weight)/sum of W • Weight = 1/Variance
  • 36. Weight of studies in the 2 models
  • 37. Assumption Heterogeneity Confidence interval Fixed effect model •One true effect underlies all studies. •Differences are due to chance. Ignored Narrow Random effects mode •Effect size varies amongst studies. •Difference are not due to chance Taken into account Wider
  • 38. Which model to use ? • If significant clinical or statistical heterogeneity is present use the random effects model. Otherwise use fixed effect model. • Clinical heterogeneity: Age, population, dose of intervention, method of outcome assessment. • Statistical heterogeneity.
  • 39. DISPLAYING THE RESULTS: FOREST PLOT
  • 40. Forest plot • The typical graph used for displaying results of a meta- analysis: forest plot • Blobbogram • At one glance we can see the effect of individual studies as well as the overall effect.
  • 41.
  • 42.
  • 43. • The horizontal axis usually represents the scale of statistics. (OR, RR, ARR, SMD etc). • The vertical line is known as the “line of null effect.” • This line is placed at the value where there is no association between an exposure and outcome. • For OR, RR the vertical line passes through 1. • For ARR, MD the vertical line passes through 0.
  • 44.
  • 45.
  • 47. • Effect estimates of individual studies are represented by boxes. • Size of the box represents the weight of the study. • The horizontal line represents the 95% confidence intervals of the study. • Any study line which crosses the line of null effect does not illustrate a significant result.
  • 48.
  • 49.
  • 51. • The diamond represent the overall effect estimate. • A vertical line through the vertical points of the diamond, represents the overall effect. • The horizontal points of the diamond represent the 95% confidence interval of this combined point estimate. • If the horizontal tips of the diamond cross the vertical line, the combined result is not significant.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56. DEMO: HOW TO DO ANALYSIS IN REVMAN
  • 57. Hypothetical Meta-analysis • Intensified ATT regimen Vs Standard ATT regimen for management of TBM. • P= TBM patients >18 years • I= intensified ATT (Levofloxacin plus HRZS) • C= standard ATT (HRZS) • O= death at 6 months • Search Literature • Narrow down the articles • Data extraction
  • 58.
  • 59.
  • 60.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.
  • 66.
  • 67.
  • 68.
  • 69.
  • 70.
  • 71.
  • 72.